Here we report the efficacy of glucagon in a dose-titrating regimen to demonstrate real-world therapeutic benefit that may support design and clinical development of novel glucagon analogs in patients with CHI: [https://clinicaltrials.gov/ct2/show/NCT03777176]. The gene discussed is GCG; the disease is congenital isolated hyperinsulinism.